Natco Pharma says USFDA inspection at Chennai facility ends with zero observations

In a regulatory filing, Natco Pharma announced "successful completion of regulatory inspection from the US Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) facility in Chennai, India, conducted during the period July 8–12, 2019".

PTI

July 15, 2019 / 10:59 AM IST

live

bselive
nselive

Volume

Todays L/H

Natco Pharma on Monday said the US health regulator has completed the inspection of its Chennai facility, and it ended with zero observations.

In a regulatory filing, Natco Pharma announced "successful completion of regulatory inspection from the US Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) facility in Chennai, India, conducted during the period July 8–12, 2019".

"The regulatory audit resulted in zero observations," the company added.

Shares of Natco Pharma were trading 0.35 per cent higher at Rs 529.95 apiece on BSE.

PTI

Tags: #Business #Companies

first published: Jul 15, 2019 10:51 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Invest in Commercial Real Estate Fractionally

Expert Trading Guidance

Natco Pharma says USFDA inspection at Chennai facility ends with zero observations

In a regulatory filing, Natco Pharma announced "successful completion of regulatory inspection from the US Food and Drug Administration (USFDA) for its active pharmaceutical ingredient (API) facility in Chennai, India, conducted during the period July 8–12, 2019".